Literature DB >> 17435543

Staging systems for papillary thyroid carcinoma: a review and comparison.

Brian Hung-Hin Lang1, Chung-Yau Lo, Wai-Fan Chan, King-Yin Lam, Koon-Yat Wan.   

Abstract

OBJECTIVE: To find out the most predictive staging system for papillary thyroid carcinoma (PTC) currently available in the literature.
BACKGROUND: Various staging systems or risk group stratifications have been used extensively in the clinical management of patients with PTC, but the most predictive system for cancer-specific survival (CSS) based on distinct histologic types remains unclear.
METHODS: Through a comprehensive MEDLINE search from 1965 to 2005, a total of 17 staging systems were found in the literature and 14 systems were applied to the 589 PTC patients managed at our institution from 1961 to 2001. CSS were calculated by Kaplan-Meier method and were compared by log-rank test. Using Cox proportional hazards analysis, the relative importance of each staging system in determining CSS was calculated by the proportion of variation (PVE).
RESULTS: All 14 staging systems significantly predicted CSS (P < 0.001). The 3 highest ranked staging systems by PVE were the Metastases, Age, Completeness of Resection, Invasion, Size (MACIS) (18.7) followed by the new AJCC/UICC 6th edition tumor, node, metastases (TNM) (17.9), and the European Organization for Research and Treatment of Cancer (EORTC) (16.6).
CONCLUSIONS: All of the currently available staging systems predicted CSS well in patients with PTC regardless of which histologic type from which they were derived. When predictability was measured by PVE, the MACIS system was the most predictive staging system and so should be the staging system of choice for PTC in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17435543      PMCID: PMC1877011          DOI: 10.1097/01.sla.0000250445.92336.2a

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  46 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  Prognostic factors in patients with differentiated thyroid carcinoma.

Authors:  T Steinmüller; J Klupp; N Rayes; F Ulrich; S Jonas; K J Gräf; P Neuhaus
Journal:  Eur J Surg       Date:  2000-01

3.  Extent of surgery for intermediate-risk well-differentiated thyroid cancer.

Authors:  S Beenken; D Roye; H Weiss; M Sellers; M Urist; A Diethelm; H Goepfert
Journal:  Am J Surg       Date:  2000-01       Impact factor: 2.565

4.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.

Authors:  S A Hundahl; B Cady; M P Cunningham; E Mazzaferri; R F McKee; J Rosai; J P Shah; A M Fremgen; A K Stewart; S Hölzer
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

5.  Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.

Authors:  S Hölzer; C Reiners; K Mann; M Bamberg; M Rothmund; J Dudeck; A K Stewart; S A Hundahl
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

Review 6.  Thyroid carcinoma.

Authors:  Steven I Sherman
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

7.  Papillary thyroid carcinoma: prognostic index for survival including the histological variety.

Authors:  S O Sebastian; J M Gonzalez; P P Paricio; J S Perez; D P Flores; A P Madrona; P R Romero; F J Tebar
Journal:  Arch Surg       Date:  2000-03

8.  Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.

Authors:  Brian Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg Oncol       Date:  2007-02-21       Impact factor: 5.344

9.  Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute.

Authors:  Sin-Ming Chow; Stephen C K Law; Siu-Kie Au; To-Wai Leung; Paddy T M Chan; William M Mendenhall; Wai-Hon Lau
Journal:  Head Neck       Date:  2002-07       Impact factor: 3.147

10.  Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.

Authors:  Christian Passler; Gerhard Prager; Christian Scheuba; Klaus Kaserer; Georg Zettinig; Bruno Niederle
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

View more
  73 in total

1.  Thyroid cancer presentation and treatment in the United States.

Authors:  Lindsey Enewold; Linda C Harlan; Jennifer L Stevens; Elad Sharon
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

3.  A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis.

Authors:  Muneki Hotomi; Iwao Sugitani; Kazuhisa Toda; Kazuyoshi Kawabata; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

4.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

Review 5.  Managing newly diagnosed thyroid cancer.

Authors:  Anna M Sawka; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  CMAJ       Date:  2013-10-07       Impact factor: 8.262

6.  Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Ni Wang; Rong Jiang; Jun-Yan Yang; Cui Tang; Lei Yang; Man Xu; Qi-Feng Jiang; Zhi-Min Liu
Journal:  J Mol Histol       Date:  2013-11-26       Impact factor: 2.611

7.  The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer.

Authors:  Varlık Erol; Özer Makay; Gökhan İçöz; Timur Köse; Yeşim Ertan; Ülkem Yararbaş; Mahir Akyıldız; Mustafa Yılmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-03-01

8.  Cancer: QTNM: a simplified TNM or just another staging system?

Authors:  Brian H H Lang; Chung-Yau Lo
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

9.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

10.  Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China?

Authors:  Lizhe Ai; Yaqin Yu; Xiaoli Liu; Chong Wang; Jieping Shi; Hui Sun; Qiong Yu
Journal:  Front Med       Date:  2014-01-23       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.